RP-HPLC method development and validation for bedaquiline fumarate to evaluate its forced degradation behaviour and stability in official dissolution media

RP-HPLC method development and validation for bedaquiline fumarate to evaluate its forced degradation behaviour and stability in official dissolution media

Abstract Background A simple, rapid and accurate reverse phase RP-HPLC method for the validation of antitubercular drug bedaquiline fumarate (BQF) was developed. The stability and forced degradation behaviour of bedaquiline fumarate (BQF) in official dissolution media (0.01 N HCl) and methanol were...

Full description

Bibliographic Details
Main Authors:	Vishwas Pardhi, Geetanjali Pant, S. J. S. Flora
Format:	Article
Language:	English
Published:	SpringerOpen 2020-07-01
Series:	Future Journal of Pharmaceutical Sciences
Subjects:	Antitubercular Bedaquiline fumarate Accuracy Precision Stability Hydrolytic degradation
Online Access:	http://link.springer.com/article/10.1186/s43094-020-00061-x

Similar Items

Quantitative Study of Impurities in Bedaquiline Fumarate: Identification and Characterization of Its Three Degradation Products Using HPLC, LC/ESI-MS, and NMR Analyses
by: Xiao-Wen Zhang, et al.
Published: (2023-03-01)

Real World Experience of Bedaquiline-Based Anti-Tubercular Regime in Multi-Drug Resistant Tuberculosis.
by: Vikas Marwah, et al.
Published: (2025-01-01)

Bedaquiline as Treatment for Disseminated Nontuberculous Mycobacteria Infection in 2 Patients Co-Infected with HIV
by: Eliza Gil, et al.
Published: (2021-03-01)

Forced degradation of mometasone furoate and development of two RP-HPLC methods for its determination with formoterol fumarate or salicylic acid
by: Ramzia I. El-Bagary, et al.
Published: (2016-05-01)

Coadministration of bedaquiline and pyrifazimine reduce exposure to toxic metabolite N-desmethyl bedaquiline
by: Yangming Ding, et al.
Published: (2023-10-01)

Bedaquiline Inhibits the ATP Synthase in Mycobacterium abscessus and Is Effective in Infected Zebrafish
by: Dupont, Christian, et al.
Published: (2018)

Validated stability-indicating RP-HPLC assay method for fesoterodine fumarate in pharmaceutical products
by: Onur PINARBASLI, et al.
Published: (2023-05-01)

Cardiac toxicity of fluoroquinolones and bedaquiline
by: G. N. Mozhokinа, et al.
Published: (2019-05-01)

Recent advancements in tuberculosis (TB) treatment regimens
by: Shyamala Ravikoti, et al.
Published: (2025-02-01)

Bedaquiline in the treatment of extensively drugresistant tuberculosis
by: T. I. Morozova, et al.
Published: (2022-04-01)

Bedaquiline: Current status and future perspectives
by: Saeed Khoshnood, et al.
Published: (2021-06-01)

Spontaneous mutational patterns and novel mutations for bedaquiline and clofazimine resistance in Mycobacterium tuberculosis
by: Jin Shi, et al.
Published: (2023-10-01)

In Vitro Evaluation of Poly(lactide-co-glycolide) In Situ Forming Gels for Bedaquiline Fumarate Salt and Pharmacokinetics Following Subcutaneous Injection in Rats
by: Sandy Van Hemelryck, et al.
Published: (2021-08-01)

Investigation of bedaquiline resistance and genetic mutations in multi-drug resistant Mycobacterium tuberculosis clinical isolates in Chongqing, China
by: Yan Hu, et al.
Published: (2023-02-01)

Distribution of Minimum Inhibitory Concentrations and Resistance-associated Gene Mutations in Multidrug-resistant Mycobacterium tuberculosis Strains from Southern Türkiye: Insights on Bedaquiline, Delamanid, and Linezolid
by: Huda Ahmed, et al.
Published: (2024-12-01)

Bedaquiline resistance pattern in clofazimine-resistant clinical isolates of tuberculosis patients
by: Yuanyuan Shang, et al.
Published: (2023-06-01)

Mitochondrial dysfunction induced by bedaquiline as an anti-Toxoplasma alternative
by: Yuehong Shi, et al.
Published: (2023-12-01)

Bedaquiline in the treatment regimen of multidrugresistant tuberculosis (clinical observation)
by: V. A. Aksenova, et al.
Published: (2020-11-01)

Targeting bedaquiline mycobacterial efflux pump to potentially enhance therapy in Mycobacterium abscessus
by: Anandi Martin, et al.
Published: (2020-01-01)

Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study
by: Nazir A. Ismail, et al.
Published: (2018-02-01)

Identification of urine biomarkers predictive of prolonged QTc interval in multidrug-resistant tuberculosis patients treated with bedaquiline
by: Jiajia Yu, et al.
Published: (2024-05-01)

Prolonged use of bedaquiline in the treatment for MDR-TB in a child
by: Marina F. Gubkina, et al.
Published: (2021-01-01)

Detection of a historic reservoir of bedaquiline/clofazimine resistance-associated variants in Mycobacterium tuberculosis
by: Camus Nimmo, et al.
Published: (2024-02-01)

Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid
by: Hoon Hee Lee, et al.
Published: (2020-09-01)

Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy
by: Luigi R. Codecasa, et al.
Published: (2017-01-01)

Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California
by: Shereen Katrak, et al.
Published: (2021-05-01)

Efficacy and safety of regimen containing bedaquiline in children with drug-resistant tuberculosis
by: V. A. Aksenova, et al.
Published: (2021-10-01)

Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis
by: Yuhong Liu, et al.
Published: (2021-01-01)

Hydrolytic degradation of composite resins: effects on the microhardness
by: Josué Martos, et al.
Published: (2003-12-01)

The emerging threat of fluroquinolone-, bedaquiline-, and linezolid-resistant Mycobacterium tuberculosis in China: Observations on surveillance data
by: Shanshan Li, et al.
Published: (2024-01-01)

Low Rate of Acquired Linezolid Resistance in Multidrug-Resistant Tuberculosis Treated With Bedaquiline-Linezolid Combination
by: Jian Du, et al.
Published: (2021-05-01)

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
by: Uzma Khan, et al.
Published: (2019-08-01)

Synthetic Studies to Help Elucidate the Metabolism of the Preclinical Candidate TBAJ-876—A Less Toxic and More Potent Analogue of Bedaquiline
by: Peter J. Choi, et al.
Published: (2020-03-01)

Evaluation of hydrolytic degradation of bionanocomposites through fourier transform infrared spectroscopy
by: Raquel do Nascimento Silva, et al.

RP-HPLC method development and validation for simultaneous estimation of telmisartan, rosuvastatin calcium, and amlodipine besylate in combination
by: Rujuta P. Mistry, et al.
Published: (2022-02-01)

Effectiveness and safety of regimen containing bedaquiline and delamanid in patients with drug-resistant tuberculosis
by: Oki Nugraha Putra, et al.
Published: (2024-04-01)

Early efficacy of individual regimens containing bedaquiline in patients with drug resistant tuberculosis
by: Oki Nugraha Putra, et al.
Published: (2023-01-01)

The exceptions that prove the rule—a historical view of bedaquiline susceptibility
by: Paolo Miotto, et al.
Published: (2024-03-01)

Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations
by: Hu MH, et al.
Published: (2016-12-01)

Bedaquiline Effect Towards QT Interval in Drug Resistant Tuberculosis (DR-TB): A Systematic Review
by: Arya Marganda Simanjuntak, et al.
Published: (2023-09-01)